Natalie Hyland

Natalie Hyland currently serves as the Head of Clinical Operations at Grey Wolf Therapeutics, a position held since February 2023. Previously, Natalie was the Senior Director, Early Clinical Lead at Adaptimmune from March 2017 to February 2023 and held multiple roles at Bio Products Laboratory Limited, GSK, Cancer Research UK, Amgen, Kendle International Inc, Holdsworth House Medical Practice, and Hammersmith Medicines Research Ltd. Natalie’s extensive experience in clinical operations and management spans nearly two decades, beginning with early roles as Clinical Trial Coordinator and Clinical Research Associate, leading to senior leadership positions in clinical development. Natalie holds a degree from the University of Leeds, completed between 1998 and 2001.